The notes shall be convertible into common stock of Accuray.6877 shares of common stock per $1,000 principal amount of the notes, which is the same as a short conversion price of approximately $5.33 per share, representing an 20 approximately.0 percent conversion premium based on the closing sale price of Accuray's common stock of $4.on February 7 44 per share, 2013. The notes will mature on February 1, 2018. Accuray might not redeem the notes prior the maturity date.. Accuray announces pricing of $100 million convertible senior notes due 2018 Accuray Included today announced the prices of its supplying of $100 million aggregate principal amount of 3.50 percent convertible senior notes due 2018 . The notes are on offer and sold to certified institutional purchasers pursuant to Rule 144A beneath the Securities Work of 1933, as amended.Various societies have had success in bringing about higher acceptance of condom use. Many studies show that most people who understand they are positive wish to safeguard their partners. Insufficient option of condoms, generic packaging and retail price are significant factors in failure to use condoms. Combined attempts that include encouraging the widespread use of condoms, quick testing and universal access to antiretroviral treatment shall bring new infections down drastically. AHF currently provides health care and/or services to more than 100, 000 individuals in 21 countries worldwide in the US, Africa, Latin America/Caribbean and the Asia Pacific Region.
Abraxis BioScience’s Phase 3 trial comparing ABRAXANE with Taxol injection meets primary endpoint Abraxis BioScience, Inc.D., at the University of NEW YORK Lineberger Comprehensive Cancer Middle.